Most current AAV programs rely on transient production, a process requiring multiple GMP plasmids for every batch. This method often drives up operational costs, constrains scalability, and creates hurdles for consistent quality. Developing stable production systems has historically proven difficult due to the complex interdependencies of viral genetics.
Minaris and Asimov Partner to Scale AAV Gene Therapy Production
Manufacturing challenges in AAV gene therapy face a potential shift as Minaris and Asimov announce a strategic partnership. By integrating Minaris’ proprietary OXGENE technology into Asimov’s AAV Edge producer cell lines, the companies aim to overcome current limitations in production titers and product consistency for viral vectors.
Asimov’s AAV Edge system utilizes synthetic biology to engineer high-titer, clonal producer cell lines. Eytan Abraham, Chief Commercial & Technology Officer at Minaris, noted that the collaboration reflects a move toward democratizing viral vector technologies to better support patient access. Raja Srinivas, co-founder of Asimov, emphasized that adding Minaris’ engineering expertise to their existing toolkit will enable a production system purpose-built for the next generation of therapeutic development. This deal reinforces Minaris' role as an integrated partner, linking its OXGENE development capabilities with broader commercial manufacturing services.
Comments (0)
No comments yet. Be the first!